News, Resources, Updates
A scientific hub to keep you informed about our latest research and company updates.
InnoSer and OrganoTherapeutics to Offer Midbrain Organoids
InnoSer is joining forces with OrganoTherapeutics to make midbrain organoids available for screening and development of pharmaceutical compounds. This partnership will enable providing midbrain organoids commercially as a platform for Parkinson’s disease research. CEO...
InnoSer and TheraIndx Strategic Partnership
InnoSer and TheraIndx announce their strategic partnership to better serve pharmaceutical and biomedical companies worldwide. Jan Bartels, the CEO of InnoSer, states: “Both companies offer unique service portfolios and bring a lot of aligned added value to our global...
InnoSer gets new cell culture facilities
InnoSer is expanding its infrastructure to better its in vitro services. These specialized services include syngeneic oncology models, PBMC and immune population work in vitro/ex vivo, organoid culture, PDX passage work and any in vitro compound screening on fresh...
Eurostars grant for MINDMAP
53 million people were affected by Alzheimer’s Disease (AD) in 2013. This was a steep rise from 26.6 million in 2005, and the predictions for 2050 rise further to 106 million cases. Despite the growing demand for AD medicines not only to stabilize but also to treat...
Leap into the future; Development of a PDXO drug screening platform
InnoSer NV, a young and innovative Belgium based Contract Research Organization (CRO) has received an over € 1.6 million grant from the Flemish VLAIO. This development grant is awarded to set up a PDXO screening platform in partnership with Vrije...
info@innoserlaboratories.com